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Active Pharmaceutical Ingredients (API) crystallized in its co-crystal form is believed to be able to improve the physicochemical proper-
ties of its pure crystal. Carbamazepine (CBZ) and saccharin (SAC) were used in this study in investigation of effect of solvents and crys-
tallization methods on the formation of CBZ-SAC co-crystal. There were four different solvents (acetonitrile, ethanol, ethyl acetate and 
propanol) and two crystallization methods (slurry and stirring crystallization) used in this study. The crystals produced were character-
ized by Differential Scanning Calorimetry (DSC), Powder X-Ray Diffraction (PXRD), Fourier Transform Infrared (FTIR) and optical 
microscopy. The findings revealed that only Form I of CBZ-SAC co-crystals was successfully formed for all parameters under studied. It 
was concluded that the type of solvents, crystallization methods and CBZ:SAC ratio used in this study did not play an important role on 
the CBZ-SAC Form I co-crystal formation for this system.    
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1. Introduction 
In pharmaceutical industry, crystallization process of polymorphs 
and solvated crystals need to be controlled as it can affect the bio-
availability, stability, solubility, and morphology of pharmaceuti-
cal products [1]. Crystal form is very important in determining the 
performance of a dosage form [2]. This is true for compounds that 
restricted in drug delivery such as low aqueous solubility, slow 
dissolution in gastrointestinal media and low permeability.  
Carbamazepine (CBZ) is one of the water insoluble drugs used for 
over 30 years as an anti-epileptic agent and requires high dosage 
for therapeutic effect. CBZ has four anhydrous polymorphic forms 
and can form as solvates and dihydrate from aqueous solutions [3, 
4]. Saccharin (SAC) is a sweetener and one of the most popular 
co-crystal former (CCF) for producing new pharmaceutical co-
crystals and a well-known co-former to form 1:1 ratio in co-crystal 
lattice with CBZ [4]. 
Solvent is one of the factors that affecting the formation of co-
crystal forms [5] and sometimes resulted in polymorphic changes 
of CBZ [6]. In addition, final crystal products such as crystal size 
and morphology also can be affected by the choices of solvent 
[7,8]. The effect of solvent on crystallization processes is crucial 
for understanding and developing methods to determine crystal 
forms [9]. Methods used for co-crystallization process also played 
an important role in determining the polymorphism of co-crystal 
produced such as antisolvent [10], polymer-assisted hetero-
nucleation approach [11] and fast evaporation [12]. Nonetheless, 
there is no single promising method can produce a stable form of a 
given compound and thus initiated the methods chosen in this 
screening process.  
The objective of this study is to assess the CBZ-SAC co-crystals 
form from various stoichiometric ratios between API and CCF in 
different solvent systems (acetonitrile, ethanol, ethyl acetate and 
propanol). The methods of crystallization used in this study were 
stirring and slurry crystallization methods. 
2. Materials and methods 
2.1. Chemicals 
Carbamazepine (CBZ) and saccharin (SAC) were obtained from 
ECA Corporation USA and Sigma Aldrich, respectively. Absolute 
ethanol (EtOH 99.4 %), acetonitrile, ethyl acetate and propanol 
were obtained from Fisher Scientific Malaysia and used as the 
solvent in producing co-crystals. 
2.2. Experimental methods 
The experimental works were conducted using slurry and stirring 
crystallization methods. Ten mol ratios of SAC/CBZ were pre-
pared starting from 0.5 mol and the rest of samples from 1.0 to 3.0 
mol are with the interval of 0.25 mol each. The crystals produced 
from the crystallization experiments then were filtered using   
vacuum filter at room temperature before undergo characterization 
analysis.  
In slurry crystallization method, mixture of both pure components 
with a known mol ratio was slurried in a conical flask with 10 mL 
of ethanol and stirred in orbital shaker for 72 hours at room tem-
perature. While for stirring crystallization method, a mixture of 
CBZ and SAC were stirred in 10 mL of ethanol in a vial with 
magnetic stirrer for 72 hours at room temperature.  
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2.3. Characterization analysis 
Differential Scanning Calorimetry (DSC) Q1000 was used to de-
termine the melting point of the crystal. For a uniform thermal 
contact with the crucible pan, a mortar and pestle was used to 
ground the sample crystals. The sample was weighed to between 2 
and 3 mg in standard aluminum pan and analyzed in the DSC from 
25 to 300°C with heating rate of 10°C/min.  
Powder X-Ray Diffraction (PXRD) (RIGAKU (Miniflex ii)) was 
used to identify the powder pattern profile of the sample. A copper 
X-ray tube was used to generate the X-rays, which operated at 30 
kV and 15mA. The angular range used was from 5° to 40° for 2θ 
(angle). The step size and step time were 0.01 and 1 second/step, 
respectively. 
Fourier Transform Infrared (FTIR) (Thermo Scientific) was used 
to identify the presence of specific functional groups of the mole-
cule. Spectra were collected in the range of 4000-600 cm-1 using 
32 scans per spectrum with a resolution 4 cm-1 for each sample 
was used for the analysis. 
Optical microscopy was used to observe the shape of the crystals 
obtained. Optical microscopy with magnification of 5x was used 
to observe the morphology of the co-crystals. 
3. Results and discussion 
3.1. Differential scanning calorimetry (DSC) 
Melting point of the pure components and co-crystal produced 
were determined by DSC. Fig. 1 shows the DSC results for CBZ, 
SAC and CBZ-SAC co-crystal. The melting point of SAC was 
227°C [13]. For CBZ, the endothermic peak at 172°C represents 
the transformation of CBZ Form III to Form I in which 191°C is 
the melting point of CBZ Form I [3]. 
The polymorphic forms of co-crystal can also be determined by 
mol ratios of CCF/API [14]. All resulted solid crystals show melt-
ing point in the range of 173-177°C, which indicate the formation 
of CBZ-SAC co-crystal Form I [10-12, 15]. However, there is an 
additional peak at 158-160°C for crystal obtained from propanol 
solvent system using slurry method (i.e. stoichiometric ratios: 
1.25-3.00), stirring method (i.e. stoichiometric ratio: 0.50) and 
from ethyl acetate solvent system of the stirring method (i.e. stoi-
chiometric ratio: 3.00). This peak suggests the formation of CBZ 
phase at the initial crystallization process [10]. Other crystalline 
samples produce peak at 224-230°C, which indicate the existence 
of pure SAC in final crystal formed are summarized in Table 1. 
Fig.1: PXRD pattern profile for (a) pure CBZ; (b) SAC: CBZ (1.50:1.00) 
in ethanol solvent for stirring method; (c) SAC:CBZ (3.00:1.00) in propa-
nol solvent for slurry method; (d) pure SAC. 
3.2. Powder x-ray diffraction (PXRD) 
The pattern profiles from PXRD were compared between the pure 
components and solid crystal produced, as shown in Fig. 2. The 
pattern profile for pure component CBZ is compatible to the   
polymorph of anhydrous CBZ Form III [3], while the SAC profile 
peak shown in this work is in a good agreement with reported by 
previous study [16]. 
 
Fig. 2: PXRD pattern profile for (a) pure CBZ; (b) SAC : CBZ (1.50 : 
1.00) in ethanol solvent for stirring method; (c) SAC : CBZ (3.00 : 1.00) in 
propanol solvent for slurry method; (d) pure SAC. 
 
CBZ-SAC co-crystal Form I has successfully formed in all sol-
vents using both methods [4, 17]. However, crystals grown in 
propanol and ethyl acetate show additional peaks at 9.4o, 22.7o and 
27.4o, and three consecutive peaks at 14.8o, 15.4o and 16o which 
indicate the presence of pure SAC in the samples (refer Fig. 1(c)). 
The DSC results also show an additional peak in the analysis 
which corresponds to pure SAC. This result also reflects that pos-
sibly that the CBZ phase transformation does not takes place in 
propanol and ethyl acetate. Strong diffraction peaks at 4.9o and 
14.9o, which are used to identify the CBZ-SAC co-crystal Form II 
[11], are not visible in all samples diffraction in this study. 
 
Table 1 summarizes the results for co-crystals recovered from 
various stoichiometric ratios, methods and solvents used in this 
study. However, for some ratios: (1) stoichiometric ratios: 0.50 for 
acetonitrile, ethanol and ethyl acetate in slurry method, and for 
ethyl acetate in stirring method; and (2) stoichiometric ratios: 
0.50-1.00 for acetonitrile in stirring method, insufficient solid 
crystals were produced due to small quantity of pure components 
used at the beginning of the experiment, and hence no result can 
be reported for this ratio. In slurry method, 100% conversion 
CBZ-SAC co-crystal can only be formed in 1.00 stoichiometric 
ratio for acetonitrile, while for ethanol and propanol solvent, the 
co-crystal can be formed from solution with CBZ:SAC ratio up to 
2.00 and 1.50 ratios respectively. The solution with higher ratios 
also can form co-crystal but the SAC crystals were also detected 
and present as a solid mixture. This probably due to the solution 
already reached SAC solubility limit and no longer could dissolve 
in the solution and precipitated out. Crystal grown in ethyl acetate 
using slurry method shows mixtures of both co-crystal and pure 
SAC in their final product. Meanwhile, for stirring method, the 
mixture of both components were found to form in 2.00 ratio in 
acetonitrile, 2.25 ratio in ethyl acetate and 2.50 ratio and above in 
ethanol. For all ratios, crystals produced in propanol and using 
stirring method formed mixtures of co-crystal and pure SAC. The 
best crystallization method to produce co-crystal is by stirring 
method as CBZ-SAC co-crystal are able to be formed in solution 
with higher ratios without the presence of pure components crys-
tals, compared to slurry method. Meanwhile, ethanol is the best 
solvent to be used as pure SAC more soluble in this solvent com-
pared to the other solvents used.  
Therefore, from DSC and PXRD analysis, it can be concluded that 
only one polymorph are successfully formed in this study which 
was CBZ-SAC co-crystal Form I. Thus, mol ratios, solvents and 
methods used in this study did not play an important role in poly-
morphism changes of CBZ-SAC co-crystal. However, other meth-
ods and solvents can be used to further study the polymorphs of 
co-crystal as it has been reported that polymorph changes in CBZ-
SAC co-crystal occurred in different method [20] and additional 
of polymer [11]. 
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0.50 - - - - - -  - 
1.00  -  -    - 
1.25    -    - 
1.50    -    - 
1.75    -     
2.00    -     
2.25         
2.50         
2.75         
3.00         
Stirring 
0.50 - -  - - -   
1.00 - -  -  -   
1.25  -  -  -   
1.50  -  -  -   
1.75  -  -  -   
2.00    -  -   
2.25    -     
2.50         
2.75         
3.00         
3.3. Fourier transform infrared (FTIR) 
Fig. 3 shows the FTIR results captured in this study, in which the 
presence of functional groups in a molecule can be determined by 
FTIR. The analysis of FTIR spectrum for CBZ Form III used in 
this study reveals peaks at 1675 cm-1 (C=O stretch), 1604 cm-1 due 
to vibration of (C=C) and (C=O) and 1593 cm-1 (N-H bend) [3,19]. 
Pure component SAC exhibits wavelength at 3088 cm-1 (N-H 
stretch), 1714 cm-1 (C=O stretch), and 1331 and 1173 cm-1 (-SO2 
stretch) [20, 21]. A peak shift seen in Fig. 3 could corresponds to 
N-H stretch of the amide from 3464 cm-1 for CBZ to 3494 cm-1 for 
the CBZ-SAC co-crystal Form I. Comparison of the spectrum of 
SAC and CBZ-SAC co-crystal shows a peak corresponding to 
asymmetrical stretch of -SO2 from 1331 cm
-1 in the spectrum of 
SAC to 1326 cm-1 in the spectrum of co-crystal, and the other 
characteristic peak of co-crystal Form I is 1642 cm-1 (C=O stretch). 
 
3.3. Optical microscopy 
Morphology of the co-crystal was determined by using optical 
microscopy and the pictures captured in this study is shown in 
Table 2. The shapes of the obtained crystals are plate-like for all 
samples which correspond to CBZ-SAC Form I, and in agreement 
to the findings by previous researchers [17, 18]. The size of co-
crystals in stirring method are much smaller compared to crystals 
obtained from slurry method, probably due to the mixing condi-
tion during crystallization process, in which stirring with magnetic 
stirrer was more vigorous than shaking with shaker [18]. 
4. Conclusion  
In this study, the formation of CBZ-SAC co-crystal in slurry and 
stirring method in different solvent system (acetonitrile, ethanol, 
ethyl acetate and propanol) were investigated. The PXRD analysis 
had confirmed the CBZ-SAC co-crystals Form I were successfully 
formed by both methods in all solvents system. Both methods are 
capable of producing CBZ-SAC Form I co-crystals. Therefore, 
type of solvents, crystallization methods and CBZ:SAC ratio used 
did not play an important role in determining the polymorph form 
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Table 2: Optical micrographs detailing the crystal morphology for SAC:CBZ (1.25:1.00). The magnification used was 5x.  
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